Option Bears Take Note as Citron Rocks Mallinckrodt PLC (MNK)

Citron Research is taking a toll on Mallinckrodt PLC (MNK) this afternoon

Nov 9, 2015 at 3:25 PM
facebook twitter linkedin

Mallinckrodt PLC (NYSE:MNK) is getting demolished, after notorious short seller Citron Research took a shot at the drugmaker via Twitter. In addition to comparing it unfavorably to another stock it's recently burnt -- Valeant Pharmaceuticals Intl Inc (NYSE:VRX) -- Citron suggested MNK may be gaming the reimbursement system:
Also weighing on MNK is a trial of its Acthar Gel lupus treatment, which missed its main goal. Collectively, these developments have sent the stock -- which was previously halted -- spiraling 16.5% lower to hover around $58.34, and landing on the short-sale restricted list. In fact, the equity earlier touched an annual low of $52.01. Option traders have responded en masse, with put volume surging to 13 times the expected intraday rate.

Jumping right in, buy-to-open activity is detected at a number of strikes. In the lead is the November 60 put, which traders are purchasing to wager on an extended move south of $60 by next Friday's close, when front-month options expire. Based on the volume-weighted average price (VWAP) of $4.84, these speculators need MNK to breach breakeven at $55.16 (strike less VWAP) by expiration in order to profit. However, if the shares bounce back above $60, the most the buyers risk losing is the initial premium paid.

Historically speaking, today's penchant for long Mallinckrodt PLC (NYSE:MNK) puts over calls is unusual. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the stock has racked up a 10-day call/put volume ratio of 2.12 -- with long calls more than doubling puts. What's more, this ratio ranks in the high 86th percentile of its 12-month range.

Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!